Alligator Bioscience has announced the initiation of a phase I clinical study (NCT06205849) to evaluate the safety and efficacy of mitazalimab (CD40 mAb agonist) injected intratumorally at the time of surgical irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
